Literature DB >> 16225177

The pentapeptide QYNAD does not inhibit neuronal network activity.

F Otto1, B C Kieseier, P Görtz, H P Hartung, M Siebler.   

Abstract

BACKGROUND: Controversial data was published about the sodium channel-blocking effect of the endogenous pentapeptide QYNAD, which is elevated in patients with multiple sclerosis and Guillain-Barré-syndrome. In some experiments with single cells and nerve preparations QYNAD inhibited sodium currents to the same extent as the known sodium channel blocker lidocaine whereas in other laboratory testing QYNAD failed to show any effect at all.
METHODS: Micro-electrode arrays with cultured neuronal networks are highly suitable to determine neuroactive activity of applied substances. The impact on electrophysiological parameter changes was compared between QYNAD and the established sodium channel blockers lidocaine and tetrodotoxin (TTX).
RESULTS: QYNAD did not alter network activity whereas the sodium channel blockers lidocaine (IC50 14.9 micorM) and tetrodotoxin (IC50 1.1 nM) reversibly decreased network activity in similar concentrations as in patch-clamp experiments. This decrease of spontaneous electrophysiological activity was achieved by prolonging the interburst-interval.
CONCLUSION: Although QYNAD might have mild effects on single-cell sodium currents, there is no significant effect on neuronal network function. These results raise concerns about QYNAD exhibiting a relevant impact on functional disability of the central nervous system in patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16225177     DOI: 10.1017/s0317167100004248

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  4 in total

1.  Transient reduction of spontaneous neuronal network activity by sublethal amyloid beta (1-42) peptide concentrations.

Authors:  Philipp Görtz; Jessica Opatz; Mario Siebler; Susanne Aileen Funke; Dieter Willbold; Christian Lange-Asschenfeldt
Journal:  J Neural Transm (Vienna)       Date:  2009-02-13       Impact factor: 3.575

Review 2.  Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome.

Authors:  Jane Pritchard; Richard Ac Hughes; Robert Dm Hadden; Ruth Brassington
Journal:  Cochrane Database Syst Rev       Date:  2016-11-15

3.  Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome.

Authors:  Alex Y Doets; Richard Ac Hughes; Ruth Brassington; Robert Dm Hadden; Jane Pritchard
Journal:  Cochrane Database Syst Rev       Date:  2020-01-25

Review 4.  Sodium channels and multiple sclerosis: roles in symptom production, damage and therapy.

Authors:  Kenneth J Smith
Journal:  Brain Pathol       Date:  2007-04       Impact factor: 6.508

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.